Announcement PDF ASX Announcement | 20 November 2024 AdAlta Limited (ASX:1AD) Results of Annual General Meeting MELBOURNE Australia, 20 November 2024: AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), the clinical stage drug discovery company developing novel protein and cell therapeutic products from its i-body® platform, advises that its Annual General Meeting was held today at 11:00am AEDT. In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary. All resolutions were carried with support of more than 97% of shares voted. This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD). For further information, please contact: AdAlta Limited (ASX:1AD) Tim Oldham CEO & Managing Director P: +61 3 9479 5159 E: t.oldham@adalta.com.au Media & Investor Enquiries The Capital Network Julia Maguire P: +61 2 7257 7338 E: julia@thecapitalnetwork.com.au About AdAlta Limited AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today’s most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials. AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation. The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body enabled CAR-T cell therapies (iCAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. AdAlta Limited (ASX:1AD) 15/2 Park Drive, Bundoora 3083 Victoria Australia ABN: 92 120 332 925 www.adalta.com.au 1 AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer, and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats. To learn more, please visit: www.adalta.com.au For more information Follow us on Twitter Follow us on LinkedIn 2 Disclosure of Proxy Votes Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 AdAlta Limited Annual General Meeting Wednesday, 20 November 2024 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Poll Results (if applicable) Proxy Votes Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed 1 Adoption of Remuneration Report P 255,566,630 2 Re-election of Director, Dr Paul MacLeman P 259,101,241 3 Approval of issue of STI Performance Rights to Dr Timothy Oldham, Director of the Company (or his nominee/s) P 255,526,630 4 Approval of issue of LTI Options to Dr Timothy Oldham, Director of the Company (or his nominee/s) P 255,526,630 5 Approval of Proportional Takeover Provisions P 259,039,241 6 ASX Listing Rule 7.1A (Approval of Additional 10% Placement Capacity) P 259,061,241 FOR AGAINST 251,600,758 2,725,741 98.45% 1.07% 254,690,103 3,292,138 98.30% 1.27% 247,611,988 6,674,511 96.90% 2.61% 243,901,976 10,384,523 95.45% 4.06% 256,268,286 1,464,449 98.93% 0.57% 251,835,460 5,985,650 97.21% 2.31% PROXY'S DISCRETION ABSTAIN 84,799 0 124,799 124,799 62,000 40,000 FOR AGAINST 1,240,131 352,386,714 2,725,741 0.49% 99.23% 0.77% 1,119,000 355,827,898 3,292,138 0.43% 99.08% 0.92% 1,240,131 348,397,944 6,674,511 0.49% 98.12% 1.88% 1,240,131 344,687,932 10,384,523 0.49% 97.08% 2.92% 1,306,506 357,593,587 1,464,449 0.50% 99.59% 0.41% 1,240,131 353,094,386 5,985,650 0.48% 98.33% 1.67% Results ABSTAIN OUTCOME 84,799 - 0 Carried 124,799 Carried 124,799 Carried 62,000 Carried 40,000 Carried